CTI BioPharma (CTIC) to Present Pacritinib Phase 3 PERSIST-2 Trial Data at ASH 2016 in Late-Breaking Session
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
CTI BioPharma Corp. (CTI) (Nasdaq: CTIC) announced that data from the randomized Phase 3 PERSIST-2 clinical trial comparing the investigational agent pacritinib, an oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for treatment of patients with myelofibrosis whose baseline platelet counts are less than 100,000 per microliter will be presented in a late-breaking oral presentation at the upcoming 58th American Society of Hematology (ASH) Annual Meeting, being held December 3-6 in San Diego, CA.
Myelofibrosis is associated with significantly reduced quality of life and shortened survival. Spleen enlargement (splenomegaly) is a common and debilitating symptom of myelofibrosis. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia and red blood cell transfusion requirements increase significantly.
Details of the PERSIST-2 presentation, two additional poster presentations regarding pacritinib, as well as poster presentations highlighting PIXUVRI® (pixantrone) and tosedostat, are below. Full abstracts can be accessed on the ASH website at www.hematology.org.
PERSIST-2 Oral Presentation
Results of the PERSIST-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients with Myelofibrosis (MF) and Platelet Counts Less Than 100,000/µLFirst Author: John Mascarenhas, M.D., Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY Date/Time: Tuesday, December 6 at 8:30 a.m. PTLocation: Hall ABOral Session: Late-Breaking AbstractsAbstract #LBA-5
Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in PERSIST-1, A Randomized Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (Pts) with Primary and Secondary Myelofibrosis (MF)First Author: Alessandro M. Vannucchi, M.D., CRIMM, AOU Careggi, University of Florence, Florence, ItalyDate/Time: Sunday, December 4 at 6:00-8:00 p.m. PTLocation: Hall GHPoster Session: 634. Myeloproliferative Syndromes: Clinical: Poster IIAbstract #3131
Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid LeukemiaFirst Author: Anupriva Agarwal, Ph.D., Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, ORDate/Time: Sunday, December 4 at 6:00-8:00 p.m. PT Location: Hall GHPoster Session: 802. Chemical Biology and Experimental Therapeutics: Poster IIAbstract #3514
The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- And T-Cell Phenotype – Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)First Author: Michael R. Clausen, M.D., Hematology, Aarhus University Hospital, Aarhus, DenmarkDate/Time: Saturday, December 3 at 5:30-7:30 pm PTLocation: Hall GHPoster Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Poster IAbstract #1782
A Phase 1 Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the MUK Three TrialFirst Author: Rakesh Popat, MBBS, Ph.D., University College London Hospitals NHS Foundation Trust, London, UKDate/Time: Sunday, December 4 at 6:00-8:00 p.m. PT Location: Hall GHPoster Session: 653. Myeloma: Therapy, excluding Transplantation: Poster IIAbstract #3321
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) Announces FDA Approval for VANTRELATM ER with Abuse Deterrence Technology
- FDA Approves Generic of Xyrem With REMS Program; Jazz Pharmaceuticals (JAZZ) Shares Decline
- Salem Media Group (SALM) Acquires ChristianConcertAlerts.com
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesCarl Icahn, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!